“3 Years of Tralokinumab Treatment Provides Long-Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s78, https://doi.org/10.25251/skin.6.supp.78.